GlassScriptPhysician profile
Paul Nieves
NPI 1427084045
$408.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.84 · 2020: $134 · 2021: $215.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $110.93 | 2019-2021 | |
| Aspira Women'S Health INC | $65.73 | 2021 | |
| Abbvie INC. | $40.91 | 2019-2021 | |
| Coopersurgical, INC. | $34.02 | 2020 | |
| Bausch Health US, LLC | $31.02 | 2020 | |
| Amgen INC. | $27.24 | 2020 | |
| Myovant Sciences INC. | $24.74 | 2021 | |
| Merck Sharp & Dohme LLC | $19.20 | 2019 | |
| Daiichi Sankyo INC. | $14.70 | 2020 | |
| Novo Nordisk INC | $13.84 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.56 | 2021 | |
| Radius Health, INC. | $13.04 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Nieves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.